Core Viewpoint - Biotalys has entered a strategic partnership with 21st.BIO to enhance the production of its protein-based biocontrol solutions, aiming for commercially competitive costs and efficient large-scale manufacturing [1][2][3]. Group 1: Partnership Details - The collaboration will utilize 21st.BIO's advanced precision fermentation platform, which has been refined over four decades and is proven in commercial use [2]. - This partnership is expected to strengthen Biotalys' AGROBODY platform and support the development of its product portfolio, including the upcoming commercial product EVOCA™ NG [3][4]. Group 2: Product Development and Market Strategy - EVOCA NG is designed to control fungal diseases such as Botrytis and powdery mildew, targeting a combined market of approximately USD 1.2 billion in the U.S., Europe, and Brazil [7]. - Biotalys anticipates a shorter regulatory review process for EVOCA NG due to its similarity to the previously approved EVOCA product [8]. Group 3: Financial and Funding Plans - Biotalys confirms its cash runway extends into May 2026 and is considering additional financing options, including equity from institutional investors, to support the commercialization of EVOCA NG and further development of its AGROBODY biocontrols [5][6].

U.S. Registration Marks a Significant Milestone as the First Protein-Based Biofungicide of its Kind to be Approved by the EPAGhent, BELGIUM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Press release - inside information Biotalys (Euronext: BTLS) is excited to announce it has received regulatory approval from the U.S. Environmental Protection Agency (EPA) for its first biofungicide, EVOCA™*. This product was developed using Biotalys’ AGROBODY™ technology platform and is the first protein-based biofungicide of its kind ...